Cerus (CERS): American Red Cross Implementation Highlights Increasing U.S. INTERCEPT Adoption - FBR
- Wall St. lower as earnings from some big names disappoint
- Unusual 11 Mid-Day Movers 10/25: (CWEI) (NXTD) (EYES) Higher; (DPRX) (CRBP) (CALA) Lower (more...)
- General Motors (GM) Tops Q3 EPS by 28c
- Procter & Gamble (PG) Tops Q1 EPS by 5c
- DuPont (DD) Tops Q3 EPS by 14c; Boosts FY16 EPS Outlook; Says Continuing to Work with Regulators
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
FBR Capital analyst Thomas Yip reiterated an Outperform rating and $10 price target on Cerus (NASDAQ: CERS) as American Red Cross implementation highlights increasing U.S. INTERCEPT adoption.
Yip commented, "After the market close on August 4, Cerus hosted a conference call to report its 2Q16 results and to discuss INTERCEPT's commercial and regulatory progress. We view INTERCEPT's implementation by the American Red Cross (ARC) as an important achievement in 2Q16, as it signifies a vote of confidence from one of the largest U.S. blood suppliers that we believe could encourage other blood suppliers to consider switching to INTERCEPT. We believe public concerns for a Zika virus (ZIKV) outbreak on U.S. soil will continue to encourage policy setters to prioritize bloodsupply safety and highlight INTERCEPT as the only FDA-approved option to ensure an uninterrupted blood supply in areas with active Zika transmissions. From a longerterm perspective, we think increasing public awareness for blood safety will lead to INTERCEPT's adoption by more U.S. blood suppliers. We reiterate our Outperform rating and $10 price target."
Shares of Cerus closed at $7.19 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intersil (ISIL) PT Bumped to $22 at Stifel
- T-Mobile (TMUS) Potential Capacity Crunch May Slow Momentum vs. Sprint (S) - FBR
- Cynosure (CYNO) PT, Estimates Trimmed at Stifel Despite Solid Results
Create E-mail Alert Related CategoriesAnalyst Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!